New Horizon Health, a market leader in cancer screening in China, on its Chapter 18A HKEX listing, raising approximately around HK$2 billion.
As PRC legal counsel to Credit Suisse Securities (USA) LLC and China International Capital Corporation Hong Kong Securities Limited as underwriters on the IPO and listing of Genetron Holdings Limited on the Nasdaq Global Select Market in the US on June 19, 2020.
CStone Pharmaceuticals, a leading innovative biopharmaceutical company in China, on its Hong Kong Stock Exchange listing, raising approximately HK$2.4 billion.
As the PRC and Hong Kong counsel, WuXi AppTec on its delisting from NASDAQ, its listing on the Shanghai Stock Exchange Main Board in May 2018 (raising approximately RMB2.2 billion) and its initial public offering on the Hong Kong Stock Exchange in December 2018 (raising approximately US$1 billion).
Wuxi Biologics, China’s largest service provider of biological products, on its successful IPO on the Hong Kong Stock Exchange, raising approximately HK$3.8 billion.
BeiGene in connection with its initial public offering on the Hong Kong Stock Exchange Main Board (raising approximately US$903 million) and on the New York Stock Exchange (raising about US$169 million).
Mindray, a global leading developer and provider of medical devices and solutions, on its listing on the ChiNext Board of the Shenzhen Stock Exchange, raising RMB5.9 billion. To date, this is the largest IPO on the ChiNext Board.
Konruns Pharmaceutical on its IPO and listing on the Shanghai Stock Exchange Main Board, raising approximating RMB974 million.
the underwriters on the IPO of Hua Medicine, a China-based drug development company with a focus on developing a global first-in-class oral drug for the treatment of Type 2 diabetes and one of the first to list under Chapter 18A.
JW (Cayman) Therapeutics Co. Ltd. (Stock code: 2126) as Hong Kong counsel on the listing of JW Therapeutics’ ordinary shares on the Main Board of the Stock Exchange of Hong Kong and the concurrent global offering. The listing and global offering raised approximately HK$2.3 billion (prior to exercise of the underwriters’ over-allotment option).
Harmonicare Medical, Wenzhou Kangning Hospital, Jacobson Pharma, Sihuan Pharm, Pioneer Pharma, Besunyen and Sinco Pharmaceuticals on their Hong Kong Stock Exchange IPOs.
Jinxin Fertility on its listing on the Hong Kong Stock Exchange Main Board.
沪ICP备05009743号-1 ©2020 FANGDA PARTNERS. ALL RIGHTS RESERVED